Sanofi-aventis Presents Cabazitaxel Updated Phase 3 Results

Sanofi-aventis Presents Cabazitaxel Updated Phase 3 Results
Published: 27-May-2010

Sanofi-aventis has updated results from the Phase 3 trial, Tropic, that demonstrated the investigational drug cabazitaxel plus prednisone/prednisolone, significantly improved overall survival, versus an active chemotherapy combination of mitoxantrone plus prednisone/prednisolone, in patients with metastatic hormone-refractory (castrationresistant) prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy.
Updated results of the primary end point (overall survival) showed that the combination of cabazitaxel and prednisone/prednisolone significantly reduced the risk of death by 28% [HR=0.72 (95% CI: 0.61-0.84); P<0.0001] with an improvement in the median overall survival of 15.1 months vs. 12.7 months in the mitoxantrone combination arm.

According to the Sanofi-aventis, the most frequent grade 3/4 hematological adverse events with cabazitaxel were neutropenia (81.7%) assessed by laboratory values, leukopenia (68.2%), anemia (10.5%), and febrile neutropenia (7.5%); the most frequent grade 3/4 non-hematological adverse events were diarrhea (6.2%), fatigue (4.9%), and asthenia (4.6%).

Discontinuation of treatment due to adverse events occurred in 18.3% of patients in the cabazitaxel arm and 8.4% of patients in the mitoxantrone arm. Most frequent treatment-emergent adverse events leading to discontinuation in the cabazitaxel arm were neutropenia (2.4%), hematuria (1.3%), diarrhea (1.1%) and fatigue (1.1%).

Grade 3/4 peripheral neuropathy occurred in 0.5% of patients in the cabazitaxel arm vs. 0.3% in the mitoxantrone arm. Deaths due to adverse events were 4.9% in the cabazitaxel arm (predominantly due to neutropenia and its complications) vs. 1.9% in the mitoxantrone arm.

Marc Cluzel, executive vice-president of research and development at Sanofi-aventis, said: "It is impressive to see the updated results continue to demonstrate an improvement in overall survival compared with that achieved with a standard chemotherapy regimen. These are encouraging results in a difficult-to-treat stage of prostate cancer."

Debasish Roychowdhury, senior vice president of global oncology at sanofi-aventis, said: "The development of cabazitaxel is one of many investigational compounds we hope to present to the cancer community in the months and years to come."

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.